首页> 外文期刊>Цитология >The role of phosphatidylinositol-3-kinases p85/p110 and hVPS34 in endocytosis of EGF-receptor complexes
【24h】

The role of phosphatidylinositol-3-kinases p85/p110 and hVPS34 in endocytosis of EGF-receptor complexes

机译:磷脂酰肌醇-3-激酶P85 / P110和HVPS34在EGF受体复合物的内吞作用中的作用

获取原文
获取原文并翻译 | 示例
           

摘要

The previous data (Zheleznova et al., 2001) did not enable the authors to conclude which particular wortmannin sensitive PI-3-kinase -- p85/p110 (I class PI-3-K) or hVPS34 (III class PI-3-K) -- may be involved in the regulation of EGF-receptor endocytosis. In the present work, we have shown that upon stimulation of EGF-receptor endocytosis additional structures stained with antibody against p85 appear in A431 cells, but the p85-positive compartment never co-localized with EGF-receptor-containing compartments either in control or in wortmannin-treated cells. At the same time, wortmannin treatment prevented association of hVPS34 with endosomal membranes. We have also found that early endosomal markers -- Rab5 and EEA1 (membrane association of the latter depends on Rab5 and hVPS34) -- co-localized with EGF-receptor in the juxtranuclear region during late stages of endocytosis, both in control and upon wortmannin treatment. These observations favor our suggestions that the transition of EGF-receptorsfrom early to late endosomes may occur directly in this juxtranuclear region and be tightly associated with the formation of so called multivesicular bodies (MVB), which are late endosomes per se. We suggest that wortmannin. may have no effect on earlyEEA1-dependent stage of the receptor endocytosis but blocks a transition of EGF-receptor complexes into the late endosomes by inhibiting activity of hVPS34 and removing it from membranes. The hVPS34 product PI-3-K, according to the known data, is involved in the formation of internal vesicles of MVB. Accumulation of EGF-receptors in these vesicles is believed to be necessary for the receptor degradation.
机译:以前的数据(Zheleznova等,2001)并未使作者能够得出结论哪种特定的Wortmannin敏感PI-3-激酶 - P85 / P110(I类PI-3-K)或HVPS34(III类PI-3- K) - 可参与EGF受体内吞作用的调节。在本作本作中,我们已经表明,在刺激EGF受体的内吞作用时,用抗体染色P85染色的另外的结构出现在A431细胞中,但P85阳性室从未与含EGF-受体的隔室共定,无论是对照还是控制Wortmannin治疗细胞。同时,Wortmannin治疗防止HVPS34与内体膜的关联。我们还发现早期的内体标志物 - Rab5和EEA1(后者的膜结合取决于Rab5和HVPS34) - 在内吞作用的后期和Wortmannin的后期内吞吐量期间与Juxtranuclecto的EGF受体共局存治疗。这些观察结果利益我们的建议,即早期核心早期的EGF-受体转变可以直接发生在该Juxtranuclecare区域中,并且与所谓的多猪体(MVB)的形成紧密相关,这是本身的晚期内体。我们建议Wortmannin。可能对受体内吞作用的肝硬化阶段没有影响,但通过抑制HVPS34的活性并将其从膜中除去膜来阻断EGF受体络合物的转变为晚期。根据已知数据,HVPS34产品PI-3-K涉及MVB的内部囊泡的形成。认为这些囊泡中的EGF受体的积累是受体降解所必需的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号